Hematopoietic cytokines as tumor markers in gynecological malignancies. A multivariate analysis in epithelial ovarian cancer patients

References

• Barreda DR, Hanington PC, Belosevic M. 2004. Regulation of myeloid development and function by colony stimulating factors. Dev Comp Immunol. 28:509–554.
   PubMed Web of Science ®Google Scholar
• Bast RCJr, Hennessy B, Mills GB. 2009. The biology of ovarian cancer: New opportunities for translation. Nat Rev Cancer. 9:415–442.
   PubMed Web of Science ®Google Scholar
• Bodnar L, Wcisło G, Miedzińska-Maciejewska M, Szczylik C. 2003. The role of macrophage colony-stimulating factor (M-CSF) in prognosis, diagnosis and in the treatment of epithelial ovarian cancer. Wspol Onkol. 7:412–419.
   Google Scholar
• Burke F, Relf M, Negus R, Balkwill F. 1996. A cytokine profile of normal and malignant ovary. Cytokine. 8:578–585.
   PubMed Web of Science ®Google Scholar
• Chambers SK, Yixum W, Gertz RE, Kacinski BM. 1995. Macrophage colony-stimulating factor mediates invasion of ovarian cancer cells through urokinase. Cancer Res. 55:1578–1585.
   Google Scholar
• Chambers SK, Kacinski BM, Ivins CM, Carcangiu ML. 1997. Overexpression of epithelial macrophage colony-stimulating factor (CSF-1) and CSF-1 receptor: A poor prognostic factor in epithelial ovarian cancer, contrasted with a protective effect of stromal CSF-1. Clin Cancer Res. 3:999–1007.
   PubMed Web of Science ®Google Scholar
• Chechlińska M. 2003. The role of cytokines in carcinogenesis. J Oncol. 53:648–659.
   Google Scholar
• Chechlińska M. 2008. The biology of ovarian cancer development. Voice. 18:8–15.
   Google Scholar
• Colombo N, Gorp TV, Parma G, Amant F, Gatta G, Sessa C, Vergote I. 2006. Ovarian cancer. Crit Rev Oncol Hematol. 60:159–179.
   PubMed Web of Science ®Google Scholar
• Foti E, Ferrandina G, Martucci R, Romanini ME, Benetti PP, Testa U, Mancuso S, Scambia G. 1999. IL-6, M-CSF and IAP cytokines in ovarian cancer: Simultaneous assessment of serum levels. Oncology. 57:211–215.
   PubMedGoogle Scholar
• Gadducci A, Ferdeghini M, Castellani C, Annicchiarico C, Prontera C, Facchini V, Bianchi R, Genazzani AR. 1998. Serum macrophage colony stimulating factor (M-CSF) levels in patients with epithelial ovarian cancer. Gynecol Oncol. 70:111–114.
   Google Scholar
• Gadducci A, Cosio S, Carpi A, Nicolini A, Genazzani AR. 2004. Serum tumor markers in the management of ovarian, endometrial and cervical cancer. Biomed Pharmacoth. 58:24–38.
   PubMed Web of Science ®Google Scholar
• Gorelik E, Landsittel DP, Marrangoni AM, Modugno F, Veikokhatnaya L, Winans MT, Bibgee WL, Herman RB, Lokshin AE. 2005. Multiplexed immunobead-based cytokine profiling for early detection of ovarian cancer. Cancer Epidemiol Biomark Prev. 14:981–987.
   PubMed Web of Science ®Google Scholar
• Haaften-Day C, Yu S, Fengji Xu, Yinhua Yu, Berchuck A, Havrilesky LJ, de Bruijn HWA, van der Zee GJ, Bast RCJr, Hacker NF. 2001. OVX1, macrophage-colony stimulating factor, and CA-125-II as tumor markers for epithelial ovarian carcinoma. Cancer. 92:2837–2844.
   Google Scholar
• Hennessy BT, Markman M. 2009. Development of novel agents for ovarian cancer. Update Cancer Ther. 3:119–132.
   Google Scholar
• Jasonni VM, Amadori A, Gentile G, Alesi L. 1999. Potential role of growth factors in ovarian cancer. Front Biosci. 1:24–29.
   Google Scholar
• Kacinski BM, Carter D, Khushbakhat M, Yee LD, Scata KA, Donofrio L, Chambers SK, Kuan IW, Yang-Feng T, Rohrischneider LR, Rothwell VM. 1990. Ovarian adenocarcinoma express fms- complementary transcripts and fms antigen, often with coexpression of CSF-1. Am J Pathol. 127:135–147.
   Google Scholar
• Kamińska J, Kowalska M. 2008. Clinical significance of serum tumor markers measurements in patients with ovarian cancer. Voice. 2:16–21.
   Google Scholar
• Kamińska J, Kowalska M, Kotowicz B. Pretreatment serum levels of cytokines and cytokine receptors in patients with non-small cell lung cancer, and correlations with clinicopathological features and prognosis. Oncology. 2006a; 70:115–125.
   PubMed Web of Science ®Google Scholar
• Kamińska J, Kowalska M, Kotowicz B, Fuksiewicz M. The prognostic value of cytokine levels in patients with cancer. Wspol Onkol. 2006b; 10:259–262.
   Google Scholar
• Lambeck AJA, Crijns APG, Leffers N, Sluiter WJ, Klaske A, Braid M, van der Zee AGJ, Daemen T, Nijman HW, Kast WM. 2007. Serum cytokine profiling as a diagnostic and prognostic tool in ovarian cancer: A potential role for interleukin 7. Clin Cancer Res. 13:2385–2391.
   PubMed Web of Science ®Google Scholar
• Ławicki S, Czygier M, Gacuta-Szumarska E, Knapp P, Szmitkowski M. The plasma levels and diagnostics utility of granulocyte-colony stimulating factor (G-CSF) and macrophage-colony stimulating factor (M-CSF) in ovarian cancer patients. Pol Merkur Lek. 2006a; 125:465–468.
   Google Scholar
• Ławicki S, Szmitowski M, Wojtukiewicz M. The pretreatment plasma level and diagnostic utility of M-CSF in benign breast and breast cancer patients. Clin Chim Acta. 2006b; 371:112–116.
   PubMed Web of Science ®Google Scholar
• Ławicki S, Będkowska GE, Gacuta-Szumarska E, Szmitkowski M. 2007. The plasma levels and diagnostics utility of stem cell factor and macrophage colony stimulating factor in endometrial cancer patients. Przegl Lek. 64:987–990.
   PubMedGoogle Scholar
• Ławicki S, Będkowska E, Gacuta- Szumarska E, Knapp P, Szmitowski M. 2008. The plasma levels and diagnostics utility of stem cell factor (SCF) and macrophage-colony stimulating factor (M-CSF) in cervical cancer patients. Pol Merkur Lek. 145:38–42.
   Google Scholar
• Ławicki S, Będkowska GE, Gacuta-Szumarska E, Czygier M, Szmitkowski M. 2009. The plasma levels and diagnostics utility of stem cell factor (SCF) in patients with endometrial cancer and with myoma uteri. Pol Merkur Lek. 156:609–615.
   Google Scholar
• Ławicki S, Będkowska GE, Gacuta-Szumarska E, Czygier M, Szmitkowski M. 2010. The plasma levels and diagnostic utility of selected hematopoietic growth factors in endometrial cancer patients and with myoma uteri. Pol Merkur Lek. 167:354–358.
   Google Scholar
• Ławicki S, Będkowska GE, Gacuta-Szumarska E, Szmitkowski M. 2012. Hematopoietic cytokines as tumor markers in gynecological malignancies: A multivariate analysis with ROC curve in endometrial cancer patients. Growth Factors. 30:29–36.
   PubMed Web of Science ®Google Scholar
• Liu L, Zhang X, Du Ch, Zhang Xu, Hou N, Zhao D, Sun J, Li L, Wang X, Ma C. 2009. MEK1-independent activation of MAPK and MEK1-dependent activation of p70 S6 kinase by stem cell factor (SCF) in ovarian cancer cells. Biochem Biophy Res Commun. 382:385–389.
   Google Scholar
• Milojkovic M, Hrgovic Z, Hrgovic I, Jonat W, Maass N, Buković D. 2004. Significance of CA 125 serum level in discrimination between benign and malignant masses in the pelvis. Arch Gynecol Obstet. 269:176–180.
   PubMedGoogle Scholar
• Moore RG, Brown AK, Miller MC, Skates S, Allard WJ, Verch T, Steinhoff M, Messerlian G, DiSilwestro P, Granai CO, Bast RC. 2008. The use of multiple novel tumor biomarkers for the detection of ovarian carcinoma in patients with a pelvic mass. Gynecol Oncol. 108:402–408.
   PubMed Web of Science ®Google Scholar
• Mroczko B, Groblewska M, Wereszczyńska-Siemiętkowska U, Kędra B, Konopko M, Szmitkowski M. 2006. The diagnostics value of G-CSF measurement in the sera of colorectal cancer and adenoma patients. Clin Chim Acta. 371:143–147.
   PubMed Web of Science ®Google Scholar
• Mroczko B, Groblewska M, Wereszczyńska-Siemiętkowska U, Okulczyk B, Kędra B, Łaszewicz W, Dębrowski A. 2007. Serum macrophage colony-stimulating factor levels in colorectal cancer patients correlate with lymph node metastasis and poor prognosis. Clin Chim Acta. 380:208–212.
   PubMedGoogle Scholar
• Ninci EB, Brandstetter T, Meinhold-Heerlein I, Bettendorf H, Sellin D, Bauknecht T. 2000. G-CSF receptor expression in ovarian cancer. Int J Gynecol Cancer. 10:19–26.
   Google Scholar
• Savarese DM, Valiński H, Quesenberry P, Savarese T. 1998. Expression and function of colony-stimulating factors and their receptors in human prostate carcinoma cell lines. Prostate. 34:80–91.
   PubMed Web of Science ®Google Scholar
• Savarese TM, Mitchell K, McQuain C, Campbell CL, Guardiani R, Wuu J, Ollari C, Reale F, Nelson BE, Chen A, Quesenberry PJ. 2001. Coexpression of granulocyte colony stimulating factor and its receptor in primary ovarian carcinomas. Cancer Lett. 162:105–115.
   Google Scholar
• Scholl SM, Bascou CH, Mosseri V, Olivares R, Magdelenat H, Dorval T, Palangié T, Validire P, Pouillart P, Stanley ER. 1994. Circulating levels of colony-stimulating factor 1 as a prognostic indicator in 82 patients with epithelial ovarian cancer. Br J Cancer. 69:342–346.
   PubMed Web of Science ®Google Scholar
• Shah SA, Lowe KA, Paley P, Wallace E, Anderson GL, McIntosh MW, Andersen MR, Scholler N, Bergan LA, Thorpe JD, Urban N, Drescher CW. 2009. Influence of ovarian cancer risk status on the diagnostic performance of the serum biomarkers mesothelin, HE4 and CA 125. Cancer Epidemiol Biomarker Prev. 18:1365–1372.
   PubMed Web of Science ®Google Scholar
• Skates S, Horick N, Yu Y, Xu FJ, Berchuck A, Havrilesky LJ, de Bruijn HW, van der Zee AG, Woolas RP, Jacobs IJ, Zhang Z, Bast RC. 2005. Preoperative sensitivity and specificity for early-stage ovarian cancer when combining cancer antigen CA 125 II, CA 15-3, CA 72-4, and macrophage colony-stimulating factor using mixtures of multivariate normal distributions. J Clin Oncol. 22:4059–4066.
   Google Scholar
• Suzuki M, Ohwada M, Aida I, Tamada T, Hanamura T, Nagatomo M. 1993. Macrophage colony-stimulating factor as a tumor marker for epithelial ovarian cancer. Obstet Gynecol. 82:946–950.
   PubMedGoogle Scholar
• Takagi A, Takeda S, Matsuoka K, Kinoshita K, Shimizu K. 1999. Macrophage colony-stimulating factor (M-CSF) production in vivo and in vitro in gynecologic malignancies. Int J Clin Oncol. 4:142–147.
   Google Scholar
• Urban A, Miszczyk L. 2003. Ovarian cancer – diagnostical and therapeutical dilema in oncological gynecology. Wspol Onkol. 7:294–300.
   Google Scholar
• Zhang Z, Yu Y, Xu F, Berchuck A, van Haaften-Day C, Havrilesky LJ, de Bruijn HW, van der Zee AG, Woolas RP, Jacobs IJ, Skates S, Chan DW, Bast RC Jr. 2007. Combining multiple serum tumor markers improves detection of stage I epithelial ovarian cancer. Gynecol Oncol. 107:526–531.
   PubMed Web of Science ®Google Scholar